Ambirix

GSK has launched Ambirix, a new hepatits A and B vaccine with a two-dose vaccination schedule.

Ambirix confers immunity against hepatitis A and hepatitis B infection by inducing specific anti-hepatitis A and anti-hepatitis B antibodies.

The hepatitis A component of the vaccine consists of inactivated hepatitis A virus and the hepatitis B component is a surface antigen produced by recombinant DNA technology.

Ambirix is for use in non-immune patients aged 1—15 years, and unlike Twinrix (GSK’s other combined hepatitis A and B vaccine) which requires a threedose regimen, the standard primary vaccination course consists of two doses.

The first dose should be given on an elected date and the second dose given between six and 12 months later. The vaccine should be administered in a setting where completion of the two-dose course can be assured.

Protection against hepatitis B infections may not be obtained until after the second dose; Ambirix should only be used when there is a low risk of hepatitis B infection during the vaccination course.

View Ambirix drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more